FABP3 and metabolic dysfunction-associated steatotic liver disease: In addition, increased serum levels of FABP3 have been reported in patients with metabolic syndrome and non-alcoholic fatty liver disease (51, 52), suggesting that FABP3 may serve as a biomarker of insulin resistance and subclinical myocardial damage.